Treace Medical Concepts, Inc. Share Price

Equities

TMCI

US89455T1097

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 01:30:00 27/04/2024 am IST 5-day change 1st Jan Change
10.4 USD +0.97% Intraday chart for Treace Medical Concepts, Inc. -5.20% -18.43%
Sales 2024 * 223M 18.57B Sales 2025 * 263M 21.94B Capitalization 644M 53.71B
Net income 2024 * -56M -4.67B Net income 2025 * -48M -4B EV / Sales 2024 * 3.16 x
Net Debt 2024 * 60.1M 5.01B Net Debt 2025 * 63.64M 5.31B EV / Sales 2025 * 2.69 x
P/E ratio 2024 *
-11.2 x
P/E ratio 2025 *
-12.8 x
Employees 516
Yield 2024 *
-
Yield 2025 *
-
Free-Float 72.07%
More Fundamentals * Assessed data
Dynamic Chart
Treace Medical Concepts Treats 100,000 Patients With Lapiplasty Bunion Correction MT
Transcript : Treace Medical Concepts, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Treace Medical Concepts, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (TMCI) TREACE MEDICAL CONCEPTS Reports Q4 Revenue $62.2M, vs. Street Est of $60.2M MT
Treace Medical Concepts, Inc. Provides Revenue Guidance for the Year 2024 CI
Treace Medical Concepts, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Treace Medical Concepts Says Post-Market Study of Lapiplasty Shows Patients Report 'Positive' Outcomes MT
Treace Medical Concepts, Inc. Announces Three-Year Interim Data from Its Align3d?? Post-Market Study Supporting the Use of the Lapiplasty Procedure for Treating Bunions CI
Transcript : Treace Medical Concepts, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 03:45 PM
Treace Medical Concepts Expects Q4 Revenue of Up to $62 Million MT
Truist Securities Adjusts Price Target on Treace Medical Concepts to $16 From $12, Keeps Buy Rating MT
UBS Adjusts Price Target on Treace Medical Concepts to $17 From $24, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Treace Medical Concepts to $14 From $30, Maintains Overweight Rating MT
Truist Adjusts Price Target on Treace Medical Concepts to $12 From $17, Maintains Buy Rating MT
Sector Update: Health Care Stocks Advance Premarket Friday MT
More news
1 day+0.97%
1 week-5.20%
Current month-20.31%
1 month-15.86%
3 months-18.88%
6 months+9.47%
Current year-18.43%
More quotes
1 week
10.23
Extreme 10.23
11.39
1 month
10.23
Extreme 10.23
13.24
Current year
10.23
Extreme 10.23
15.98
1 year
5.27
Extreme 5.27
27.70
3 years
5.27
Extreme 5.27
37.17
5 years
5.27
Extreme 5.27
37.17
10 years
5.27
Extreme 5.27
37.17
More quotes
Managers TitleAgeSince
Founder 52 01/14/01
Director of Finance/CFO 54 01/20/01
Compliance Officer 49 01/22/01
Members of the board TitleAgeSince
Director/Board Member 66 20/20/20
Director/Board Member 65 01/15/01
Chairman 77 01/14/01
More insiders
Date Price Change Volume
26/24/26 10.4 +0.97% 412,914
25/24/25 10.3 -3.47% 366,425
24/24/24 10.67 -1.75% 295,916
23/24/23 10.86 -2.16% 261,201
22/24/22 11.1 +1.19% 270,025

Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST

More quotes
Treace Medical Concepts, Inc. is a medical technology company. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It also has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Lapiplasty, Adductoplasty and Hammertoe PEEK Fixation Systems are comprised of single-use implant kits and reusable instrument trays. The Company sells these products to physicians, surgeons, hospitals and ambulatory surgery centers in the United States.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.4 USD
Average target price
15.86 USD
Spread / Average Target
+52.47%
Consensus